This page is an educational reference, not a product listing. Riptide Health does not supply pharmaceutical somatropin. The information below is intended to help researchers and curious readers understand what full-sequence HGH is, how it works, and how it differs from the research peptides we do supply.
⚠️ Regulatory Notice
Full-sequence HGH (somatropin) is a Schedule 4 prescription-only medicine in Australia. Riptide Health does not supply somatropin as a pharmaceutical product. This page is provided for educational purposes only. For research peptides related to GH pathways, see our catalogue below.
Looking for GH-Related Research Peptides?
Explore Riptide Health's catalogue of research-grade peptides that target the growth hormone pathway through different mechanisms.
What Is HGH?
HGH (somatropin) is the complete 191-amino acid growth hormone protein produced by the anterior pituitary gland. It regulates growth, metabolism, body composition, and cellular repair. Levels peak in adolescence and decline progressively with age — a process known as the somatopause — contributing to changes in body composition, energy, and recovery capacity.
How Does HGH Work?
HGH operates through two pathways. The first is direct binding to growth hormone receptors on muscle, fat, bone, and liver tissue. The second is hepatic production of Insulin-like Growth Factor-1 (IGF-1), which drives the majority of HGH's anabolic effects — including muscle hypertrophy, bone and cartilage growth, and cellular repair.
Approved Medical Uses
Somatropin has decades of clinical evidence supporting its approved pharmaceutical uses, including:
- Growth hormone deficiency (childhood and adult)
- Turner syndrome
- Prader-Willi syndrome
- HIV-associated lipodystrophy
- Short bowel syndrome
HGH vs Research Peptides — The Key Distinction
HGH is often confused with the research peptides that influence the growth hormone axis. They are fundamentally different compounds with different structures, mechanisms, regulatory status, and risk profiles.
| Feature | Full HGH (Somatropin) | HGH Fragment 176-191 | GH Secretagogues (CJC-1295, Ipamorelin, Sermorelin) |
|---|---|---|---|
| Structure | Complete 191-AA protein | AA 176–191 only | Synthetic peptides — not HGH |
| Mechanism | Direct GHR binding + IGF-1 | Selective lipolysis only | Stimulate pituitary GH release |
| IGF-1 elevation | Significant | Minimal | Indirect, physiological |
| Insulin disruption | Yes | Minimal | Minimal |
| TGA classification | Schedule 4 (Rx only) | Not scheduled | Not scheduled |
| Available at Riptide Health | ❌ No | ✅ Yes | ✅ Yes |
This page is provided for educational and research reference purposes only. Riptide Health does not supply somatropin or any TGA-scheduled pharmaceutical. All research peptides in the Riptide Health catalogue are distinct compounds supplied strictly for research and laboratory purposes. They are not intended to diagnose, treat, cure, or prevent any disease or medical condition and should not be administered to humans or animals. Riptide Health complies fully with all applicable Australian regulations.